20 related articles for article (PubMed ID: 29600976)
1. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH
Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Wang HF; Ning F; Liu ZC; Wu L; Li ZQ; Qi YF; Zhang G; Wang HS; Cai SH; Du J
Cancer Immunol Immunother; 2017 Mar; 66(3):355-366. PubMed ID: 27915371
[TBL] [Abstract][Full Text] [Related]
3. Function of reactive oxygen species in myeloid-derived suppressor cells.
Huang J; Zhao Y; Zhao K; Yin K; Wang S
Front Immunol; 2023; 14():1226443. PubMed ID: 37646034
[TBL] [Abstract][Full Text] [Related]
4. Possible Metastatic Stage-Dependent ILC2 Activation Induces Differential Functions of MDSCs through IL-13/IL-13Rα1 Signaling during the Progression of Breast Cancer Lung Metastasis.
Ito A; Akama Y; Satoh-Takayama N; Saito K; Kato T; Kawamoto E; Gaowa A; Park EJ; Takao M; Shimaoka M
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805039
[TBL] [Abstract][Full Text] [Related]
5. Fibronectin expression is decreased in metastatic renal cell carcinoma following endostatin gene therapy.
Chaves KC; Turaça LT; Pesquero JB; Mennecier G; Dagli ML; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2012 Sep; 66(6):464-8. PubMed ID: 22920414
[TBL] [Abstract][Full Text] [Related]
6. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma.
de Souza Braga M; Chaves KB; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2012 Jun; 66(4):237-41. PubMed ID: 22560459
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the NF-кB/p50/Bcl-3 complex in response to antiangiogenic therapy in a mouse model of metastatic renal cell carcinoma.
de Souza Braga M; da Silva Paiva KB; Foguer K; Barbosa Chaves KC; de Sá Lima L; Scavone C; Bellini MH
Biomed Pharmacother; 2014 Sep; 68(7):873-9. PubMed ID: 25113400
[TBL] [Abstract][Full Text] [Related]
8. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model.
Chaves KC; Peron JP; Chammas R; Turaça LT; Pesquero JB; Braga MS; Foguer K; Schor N; Bellini MH
Cancer Gene Ther; 2012 Aug; 19(8):558-65. PubMed ID: 22699868
[TBL] [Abstract][Full Text] [Related]
9. Endostatin gene therapy inhibits intratumoral macrophage M2 polarization.
Foguer K; Braga Mde S; Peron JP; Bortoluci KR; Bellini MH
Biomed Pharmacother; 2016 Apr; 79():102-11. PubMed ID: 27044818
[TBL] [Abstract][Full Text] [Related]
10. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
Ochoa AC; Zea AH; Hernandez C; Rodriguez PC
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):721s-726s. PubMed ID: 17255300
[TBL] [Abstract][Full Text] [Related]
11. Impact of endostatin gene therapy on myeloid-derived suppressor cells from a metastatic renal cell carcinoma.
Chaves KC; Costa EM; Teixeira LF; Bellini MH
Exp Oncol; 2018 Mar; 40(1):24-32. PubMed ID: 29600976
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
